Ra Pharmaceuticals Inc (NASDAQ:RARX), Ocular Therapeutix Inc (NASDAQ:OCUL)

Ivan Schwartz
July 17, 2017

(NASDAQ:OCUL) during the first quarter, according to its most recent disclosure with the SEC. Similar statistics are true for the second largest owner, Versant Venture Management, Llc, which owns 2,215,384 shares of the stock are valued at $14.74 million. Ocular Therapeutix earned a media sentiment score of -0.06 on Accern's scale. Columbus Circle Investors boosted its position in shares of Ocular Therapeutix by 131.4% in the first quarter.

Analysts reviewing Ocular Therapeutix, Inc. have recently updated their recommended buy/sell ratings and price targets on the stock. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock valued at $3,705,000 after buying an additional 284,200 shares in the last quarter. State Street Corp now owns 238,921 shares of the biopharmaceutical company's stock worth $2,000,000 after buying an additional 42,761 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Ocular Therapeutix during the first quarter valued at $3,394,000. Teachers Advisors LLC raised its stake in shares of Ocular Therapeutix by 47.7% in the fourth quarter. (NASDAQ:OCUL) opened at 6.33 on Friday. The firm exchanged a volume of 2.57 million shares at hands. The third largest holder is Sv Health Investors, Llc, which now holds $10.68 million worth of this stock and that ownership represents almost 5.42% of its market capitalization. Zooming out to the 200-day moving average, shares have been seen trading -22.00% away from that value. Morgan Stanley downgraded Ocular Therapeutix Inc (NASDAQ:OCUL) on Friday, October 23 to "Equal-Weight" rating. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.10.

3 analysts on average are expecting the company to report revenue of $550000 for the current quarter. The Return on Equity (ROE) value stands at -80.2%. During the same period in the previous year, the company posted ($0.35) earnings per share.

Returns and Valuations for Ocular Therapeutix, Inc.

Morata was very close to joining Manchester United - Herrera
And Herrera has assured United supporters that he will fight for De Gea to remain at Manchester United for the forseeable future. We wanted to be honest and open and give everything for him to make a decision, in case his desire was to leave.

Diego Costa posts video from holiday in Atletico Madrid shirt
The Blues' top scorer will be unable to play until January as Atletico are now under a transfer embargo. Chelsea snapped up Tiemoue Bakayoko from Monaco for £40m yesterday.

Police to release update on investigation into murdered teens in Delphi
Investigators are asking the public to study the man's facial features and contact them with any information on him. Anyone with information about the slayings or the person in the sketch is asked to call toll-free to 844-459-5786.

COPYRIGHT VIOLATION NOTICE: "Wells Fargo & Company MN Boosts Position in Ocular Therapeutix, Inc". If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & global copyright and trademark legislation.

A number of other equities analysts also recently commented on OCUL.

Ocular Therapeutix, Inc. (OCUL) has a market capitalization of 183.75 Million which suggests the company is a huge company further suggesting that the shares of Ocular Therapeutix, Inc. BTIG Research reiterated a "buy" rating and set a $13.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 21st. The rating was maintained by Cantor Fitzgerald on Monday, July 10 with "Buy". Morgan Stanley lowered shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has "Overweight" rating given on Friday, February 10 by Cantor Fitzgerald. A 5 analysts rate it as either a buy or a strong buy, while 1 believe that investors should either steer clear of (NYSE:PEG) or, if they already own its stock, sell it. The stock closing price is now trading downward to its 50 day moving average with change of -32.26%, tumbled to its 20 day moving average with figure of -30.31% and behind its 200 day moving average with value -22.00%.

On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant.

Other reports by GizPress

Discuss This Article